Rosuvastatin
A potent statin medication used to lower LDL cholesterol and triglycerides while raising HDL cholesterol, significantly reducing the risk of heart attack, stroke, and other cardiovascular events. It is generally well-tolerated and effective at low doses, making it one of the most widely prescribed cholesterol-lowering medications.
分子量
481.5390 g/mol
LogP
1.60
TPSA
149.00 Ų
リピンスキーの五則
適合
治療領域
薬物分類
作用機序
Competitive inhibitor of HMG-CoA reductase.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitive inhibitor of HMG-CoA reductase.
2D構造
Cite this structure
Embed this structure
SMILES
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O
InChI
InChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1
Molecular Formula
C22H28FN3O6S
HBD / HBA
3 / 10
回転可能結合数
10
重原子数
33
Rosuvastatin increases warfarin plasma concentrations through inhibition of CYP2C9, potentially leading to supratherapeutic INR values.
Rosuvastatin and colchicine share BCRP transporter-mediated elimination; colchicine may weakly increase rosuvastatin exposure, and both carry myotoxic potential that could be additive.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
A potent statin medication used to lower LDL cholesterol and triglycerides while raising HDL cholesterol, significantly reducing the risk of heart attack, stroke, and other cardiovascular events. It is generally well-tolerated and effective at low doses, making it one of the most widely prescribed cholesterol-lowering medications.
Competitive inhibitor of HMG-CoA reductase.
Key pharmacokinetic parameters for Rosuvastatin: Half-life: 19 hours.
Yes, Rosuvastatin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
Same Drug Class
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1496. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 446157. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="rosuvastatin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/rosuvastatin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/rosuvastatin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/rosuvastatin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="rosuvastatin"></drugfyi-drug>